Global gene therapy market is rising gradually with a healthy CAGR of 36.1% in the forecast period of 2019-2026. Increasing incidence of cancer and rare life threatening diseases and strong clinical pipeline drugs for gene therapy are major drivers for market growth. Few of the major competitors currently working in the global gene therapy market are Pfizer Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Spark Therapeutics, Inc., bluebird bio, Inc., ALLERGAN, Krystal Biotech, Inc., Amicus Therapeutics, Inc., Sarepta Therapeutics, Novartis AG, MeiraGTx Limited, Rocket Pharmaceuticals, Lonza, Biogen, Gilead Sciences, Inc., REGENXBIO Inc., uniQure N.V., Solid Biosciences Inc., Audentes Therapeutics among others.

Get Sample Report + All Related Graphs & Charts @www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gene-therapy-market&pm

Competitive Analysis:

Global gene therapy market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of gene therapy market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Definition: Global Gene Therapy Market

Gene therapy is a technique of insertion of genes into cells and tissues for treatment of any disease. In this technique the defective gene is replaced with a functional gene. It is the strategy of manipulation of expression of specific genes responsible for the disease. This therapy is a promising treatment option for a number of diseases. The application of gene therapy is wide and it is mostly used for treatment of cancer, cystic fibrosis, heart disease, diabetes, AIDS among others.

Global Gene Therapy Market  By Type (Somatic Gene Therapy, Germline Gene Therapy, Others), Gene Type (Antigen, Cytokine, Suicide, Others), Viral Vector (Retroviruses, Herpes Simplex Virus, Adenoviruses, Others), Non-Viral Vector (Naked/Plasmid Vectors, Electroporation and Others), Application (Oncology, Rare Diseases, Infectious Disease, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026

Market Drivers

Prevailing rate of cancer acts as a market driver in the forecast period
Competition among the leading pharmaceutical companies in the approval of gene therapy products is another factor boosting this market growth
Increasing investment of private and government organization in research and development of gene therapy drives the market growth
Increasing awareness about gene therapy and its applications is another factor boosting this market growth

Market Restraints

High cost associated with the treatment restricts the market growth
Side effects like unwanted immune responses also hampers the market growth

Concerns regarding the unethical use of gene therapy also hamper the market growth

Grab Your Report at an Impressive 30% Discount! Please click Here @www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-gene-therapy-market&pm

Segmentation: Global Gene Therapy Market

By Type

Somatic Gene Therapy
Germline Gene Therapy
Others

By Gene Type

Antigen
Cytokine
Suicide
Others

By Viral Vector

Retroviruses
Herpes Simplex Virus
Adenoviruses
Others

By Non-Viral Vector

Naked/Plasmid Vectors
Electroporation
Others

By Application

Oncology
Rare Diseases
Infectious Disease
Others

By End Users

Hospitals
Homecare
Specialty Clinics
Others

By Distribution Channels

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others

For More Insights Get Detailed TOC @www.databridgemarketresearch.com/toc/?dbmr=global-gene-therapy-market&pm

Key Developments in the Market:

In May 2019, AveXis, Inc., a subsidiary of Novartis AG announced establishment of a gene therapy access program for Zolgensma (onasemnogene abeparvovec-xioi) which is used for treatment of pediatric patients with spinal muscular atrophy (SMA) with bi-allelic mutations. AveXis, Inc. is dealing with payers on agreements to create novel pay-over-time options is planning to provide high support to the patients needing zolgensma for SMA
In March 2019, Thermo Fisher Scientific Inc. announced the acquisition of Brammer Bio for taking up the market of viral vector manufacturing services for gene therapy. This acquisition  proves that the growing market catches up with the demand for life-changing therapeutics in order to meet the unmet medical needs. This acquisition contributes in the fast-evolving gene therapy market

Reasons to Purchase this Report

Current and future of global gene therapy market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[email protected]

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.



Source link